CCO Oncology Podcast
169 episodes - English - Latest episode: 27 days ago -Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
Homepage Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer
March 28, 2024 16:28 - 48 minutes - 44.2 MBIn this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: Rationale for targeting PARP in prostate cancer with ARI combinations Study design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2 FDA appr...
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer
March 18, 2024 14:38 - 36 minutes - 33.5 MBIn this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including: Challenges with the pathologic testing for HER2-low expression Optimal treatment of patients with HER2-low advanced breast cancer Role of TROP-2–targeted therapies Management of ADC-associated adverse events to optimize t...
Current Considerations for Adverse Event Management With HER3-Directed Agents
December 26, 2023 19:43 - 12 minutes - 11.6 MBThe third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer. Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts Helena Yu, MD Associate Attending Departm...
Unpacking the Potential of HER3-Targeted Therapy in NSCLC
December 26, 2023 19:43 - 15 minutes - 14.2 MBThis second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including: Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab The HER2xHER3 bispecific antibody zenocutuzumab The HER3-targeted antibody–drug conjugate SHR-A2009 Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical ...
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer
December 26, 2023 05:00 - 8 minutes - 8.25 MBThis first episode in a 3-part series tackles the role of HER3 in cancer, specifically in NSCLC, and how HER3 can be effectively targeted with ADCs. Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts Helena Yu, MD Associate Attending Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Supported by an educational grant from Daii...
Expert Insight on Seminal New Clinical Trial Data Presented at the 2023 IGCS Conference Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
December 04, 2023 13:56 - 30 minutes - 28 MBIn this episode, Brian Slomovitz, MD, MS, FACOG, and Keiichi Fujiwara, MD, PhD, share their thoughts and opinions on seminal data presented at the 2023 IGCS annual meeting for endometrial, ovarian, and cervical cancers, including: Phase III NRG GY018 trial of carboplatin and paclitaxel with or without pembrolizumab followed by pembrolizumab or placebo maintenance for 2 years in patients with measurable stage III/IVA, stage IVB, or recurrent endometrial cancer. Phase III ENGOT-EN6/GOG-3031...
Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis
November 30, 2023 14:09 - 19 minutes - 18 MBIn this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including: Navitoclax (BCL-XL/BCL-2 inhibitor) Pelabresib (BET inhibitor) Imetelstat (telomerase inhibitor) Luspatercept (erythroid maturation agent) Additional strategies Presenter: Jacqueline S. Garcia, MD Assistant Professor of Medicine Harvard Medical School Dana-Farber Cancer Institute Boston, Massachusetts Link to the full pr...
A Year in Review and a Look to the Future: BTKi in CLL and MCL
November 20, 2023 05:00 - 27 minutes - 25.4 MBIn this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of: SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs...
Expert Insight on Key Updates and New Clinical Trial Data From the ESMO 2023 Congress Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
November 17, 2023 19:36 - 33 minutes - 30.6 MBIn this episode, Isabelle Ray-Coquard, MD, PhD, and Ana Oaknin, MD, PhD, provide expert insights on new clinical trial data presented at the 2023 ESMO annual congress for endometrial, ovarian, and cervical cancers, including: Results from the double-blind, randomized, placebo-controlled phase III AtTEnd trial of atezolizumab plus carboplatin/paclitaxel in advanced or recurrent endometrial cancer Randomized, multicenter, double-blind, placebo-controlled phase III DUO-E study of durvalumab p...
Expert Insights and Considerations for Precision Care With HER3-Targeted Agents in NSCLC and Breast Cancer
November 07, 2023 05:00 - 38 minutes - 35.7 MBIn this episode, Aakash Desai, MD; Narjust Florez, MD; and Paolo Tarantino, MD, discuss the biologic rationale and clinical development of agents targeting HER3 for the treatment of breast and lung cancers. The potential niche for HER3-targeted agents in these treatment landscapes is considered, with consideration of acquired resistance to previous targeted therapies and parallels to other approved antibody–drug conjugates. Their conversation covers clinical trial data from: Phase I/II stud...
Improving Care for Black Patients With Endometrial Cancer
November 06, 2023 17:21 - 26 minutes - 24.8 MBIn this episode, Dr Leslie Boyd and Adrienne Moore, a patient advocate and endometrial cancer survivor, discuss how healthcare professionals can partner with Black patients to improve the diagnosis and management of endometrial cancer (EC). Topics include: Data on racial disparities in EC survival Importance of listening to Black patients to better diagnose EC Financial and practical considerations regarding care How to help empower Black patients in shared decision-making with their car...
Expert Insight on Key Updates and New Clinical Trial Data From the ESGO 2023 Congress Informing Treatment for Cervical, Ovarian, and Endometrial Cancers
October 13, 2023 04:00 - 24 minutes - 22.9 MBIn this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the ESGO 2023 Congress for cervical, endometrial, and ovarian cancers, including: Long-Term Follow Up From Phase III SIENDO Study of Selinexor vs Pbo Maintenance in Patients With TP53wt Advanced/Recurrent Endometrial Cancer Global, Open-Label, Phase I/IIa of HER2-Targeting ADC (DB-1303) in Recurrent/Metastatic Endometrial Cancer Phase I...
New Evidence With BTK Inhibitor Therapy in CLL and MCL From SOHO 2023
October 04, 2023 15:33 - 20 minutes - 19.3 MBIn this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at SOHO 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: Matching-adjusted indirect comparison of 3 randomized phase III trials of ibrutinib for relapsed/refractory CLL Meta-analysis of cardiovascular adverse events with second-generation BTK inhibitors in CLL BRUIN: updated results of pi...
New Evidence With BTK Inhibitor Therapy in MCL From ICML 2023
August 17, 2023 20:20 - 14 minutes - 13.5 MBIn this episode, Catherine C. Coombs, MD, and Toby Eyre, MBChB, MD, discuss key trials presented at ICML 2023 evaluating the use of BTK inhibitors in mantle cell lymphoma (MCL). The discussion includes analyses of: Phase II trial of acalabrutinib with rituximab for older patients with untreated MCL BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL IMCL-2015 GELTAMO: 5-year update ibrutinib for untreated indolent MCL Presenters: Catherine C. Coombs, MD...
New Evidence With BTK Inhibitor Therapy in CLL From EHA 2023
July 28, 2023 04:00 - 27 minutes - 25 MBIn this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at EHA 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL). The discussion includes analyses of: CLL12: final results of the phase III trial of ibrutinib vs placebo in asymptomatic, treatment-naive CLL SEQUOIA: extended follow-up of zanubrutinib vs BR in treatment-naive CLL CAPTIVATE: 4-year follow-up from the fixed duration cohort of ibrutinib plus venetoclax i...
Expert Insight on Key Updates and New Clinical Trial Data From the 2023 ASCO Annual Meeting, Informing Treatment for Cervical, Ovarian, and Endometrial Cancers
June 22, 2023 13:45 - 46 minutes - 42.3 MBIn this episode, Kathleen Moore, MD, MS, and Nicoletta Colombo, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the 2023 ASCO Annual Meeting for cervical, endometrial, and ovarian cancers, including: ENGOT-EN6-NSGO/GOG-3031/RUBY: phase III study of dostarlimab plus chemotherapy followed by dostarlimab maintenance in primary advanced or recurrent endometrial cancer outcomes by BICR CCTG CX.5-SHAPE: phase III trial of radical hysterectomy and pelvic n...
Expert Insight on New Data From SGO 2023 Informing Treatment for Endometrial, Cervical, and Ovarian Cancers
May 04, 2023 11:25 - 31 minutes - 29.1 MBIn this episode, David Scott Miller, MD, FACOG, FACS, and Linda Duska, MD, MPH, provide expert insights on practice-changing data and other new findings presented at SGO 2023 in endometrial, cervical, and ovarian cancers, including: NRG GY018: randomized phase III study evaluating standard of care of carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with endometrial cancer ENGOT-EN6/GOG-3031/RUBY: randomized, placebo-controlled phase III study of...
Practical Insights on Using BCMA-Targeted Therapies in Multiple Myeloma
April 26, 2023 13:34 - 32 minutes - 29.7 MBIn this episode, Suzanne Lentzsch, MD, Ph.D., and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of BCMA-targeted therapies in the management of patients with multiple myeloma, including their experiences and challenges with implementing recent data. This overview will include a discussion of: Considerations with administration, including access challenges Sequencing Therapies Future developments with BCMA-targeted therapies Presenters: Suzanne Lentzsch, MD, PhD Professor of Me...
Contemporary Approaches to Treating Myelofibrosis: A Conversation Between Experts
April 11, 2023 04:00 - 15 minutes - 14.7 MBIn this episode, John Mascarenhas, MD, and Ruben A. Mesa, MD, FACP, discuss current best practices and emerging approaches for treating patients with myelofibrosis, including: Overall approach to treatment Use of JAK inhibitors for treating myelofibrosis Treating patients with low platelets Defining JAK inhibitor failure Unmet needs in treatment and emerging therapeutic options, including momelotinib, luspatercept, ruxolitinib add-on therapy, and other phase III approaches Presenters: ...
BRCA Testing and Adjuvant Therapy in Early Breast Cancer: Experiences and Challenges
April 05, 2023 04:00 - 25 minutes - 23 MBIn this episode, Banu Arun, MD; Allison Butts, PharmD, BCOP; and Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, discuss the role of BRCA testing and adjuvant olaparib in early breast cancer, including their experiences and challenges with implementing recent data. This overview will include discussion of: Data supporting the use of adjuvant PARP inhibition in early breast cancer and impact on BRCA testing and clinical practice The multidisciplinary role in ensuring that BRCA testing i...
Experts Discuss Claudin 18.2: A New Target for Precision Care of Gastric and Gastroesophageal Cancers
March 28, 2023 17:13 - 15 minutes - 14.5 MBIn this podcast episode, Samuel Klempner, MD, and Gregory Botta, MD, PhD, provide expert commentary on the rationale and development of novel agents under investigation for targeting claudin 18.2 in gastric and gastroesophageal cancers, with topics including: Expression patterns and function of the claudin family of proteins in normal gastric tissues Biologic rationale for utility of claudin 18.2 as an actionable therapeutic target in oncology Prognostic implications of claudin 18.2 overe...
Treatment Considerations for Patients With Essential Thrombocythemia: A Conversation Between Experts
February 23, 2023 21:30 - 21 minutes - 19.9 MBIn this podcast episode, Prithviraj Bose, MD, and Andrew Kuykendall, MD, discuss their contemporary approaches to the treatment of patients with essential thrombocythemia. The topics covered include: When to use cytoreduction therapies and which therapies to use in low-risk patients Type 1 and type 2 CALR mutations and addressing patient concerns with data from sequencing reports Experts’ thoughts on therapy options in higher-risk patients Presenters: Prithviraj Bose, MD Associate Pr...
FAQs on the Use of Asparaginase Therapy in Young and Older Adults With Acute Lymphoblastic Leukemia
February 20, 2023 21:20 - 26 minutes - 24.3 MBIn this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with acute lymphoblastic leukemia. Topics discussed include: Practical considerations for management of allergy-like reactions and hyperse...
Experts Answer Questions on Personalized Management of Patients With Myelodysplastic Syndromes
February 17, 2023 17:00 - 21 minutes - 20.2 MBIn this podcast, Rami Komrokji, MD; María Díez Campelo, MD, PhD; and Amer Zeidan, MBBS, MHS answer questions from an audience of healthcare professionals on topics related to personalized management of myelodysplastic syndromes including: Practical use of the Molecular International Prognostic Scoring System Mutational targets and other treatments in ongoing clinical trials Prophylaxis with venetoclax therapy Best practices for bone marrow transplant, including induction and salvage ...
Experts Answer Questions on the Management of Patients With T-Cell Lymphomas
February 17, 2023 17:00 - 16 minutes - 15.1 MBIn this podcast episode, Steven M. Horwitz, MD; Pamela B. Allen, MD, MSc; and Kerry Savage, MD, MSc, answer questions from an audience of healthcare professionals on topics related to the management of T-cell lymphomas, including: Use of brentuximab vedotin in ≤1% CD-30‒expressing lymphomas Strategies with JAK inhibition and epigenetic agents Allogeneic transplantation in cutaneous T-cell lymphoma Presenters: Steven M. Horwitz MD Member, Memorial Sloan Kettering Cancer Center Attending...
Individualizing Care for Patients With Triple-Negative Breast Cancer
January 18, 2023 21:30 - 36 minutes - 33.5 MBIn this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including: Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC Clinical implications of PD-L1 status on therapeutic planning for patients with metastatic TNBC Current data and treatment strategies and the future of antibo...
Contemporary Approaches to Treating Polycythemia Vera: A Conversation Between Experts
January 11, 2023 21:30 - 15 minutes - 14.6 MBIn this podcast episode, Raajit Rampal, MD, PhD, and Brady L. Stein, MD, MHS, discuss their contemporary approaches to the treatment of patients with polycythemia vera. The topics covered include: Patient presentation and goals of frontline therapy Considerations for second-line therapy in the setting of treatment intolerance Experts’ thoughts on the potential of early intervention to alter disease progression Presenters: Raajit Rampal, MD, PhD Associate Member Associate Attending Physi...
HCC Surveillance: Challenges and Opportunities
January 03, 2023 21:30 - 31 minutes - 29 MBIn this episode, David Kaplan, MD, MSc, and Tamar Taddei, MD, discuss which patients should be screened for hepatocellular carcinoma, current surveillance recommendations, barriers to implementation, emerging biomarkers in development, and unmet needs in hepatocellular carcinoma surveillance. Presenters: David E. Kaplan, MD, MSc Associate Professor Perelman School of Medicine Chief, Hepatology Section Division of Gastroenterology and Hepatology University of Pennsylvania Director of Hep...
A Patient’s Perspective on Effective Communication With the Healthcare Team: My Journey With High-Risk HR-Positive/HER2-Negative Early Breast Cancer
December 13, 2022 22:10 - 9 minutes - 8.64 MBIn this episode, Zoe Lanham, a woman with high-risk hormone receptor–positive/HER2-negative early breast cancer, discusses the importance of effective communication between patients and their healthcare team, drawing on her personal experience. Presenter: Zoe Lanham Patient Link to full program: https://bit.ly/3Fukjzk
Expert Thoughts on Studies of Interest Presented at the 2022 ESGO Annual Meeting on Gynecologic Cancers
November 29, 2022 21:30 - 27 minutes - 25.1 MBIn this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including: • Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer • Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test • Validation of NOGGO-GIS HRD assay using samples from the PAOL...
The Transgender Cancer Experience: A Conversation Between an Oncologist and a Transmasculine Individual on Navigating the Healthcare System
November 29, 2022 21:30 - 46 minutes - 43 MBIn this episode, activist and breast cancer survivor Yee Won Chong shares his experience as a transmasculine person navigating the healthcare system with Norma Steiner, MD, a gynecologic oncologist, who in turn offers her perspective on caring for patients across the gender spectrum. Topics include: 4 aspects of transgender care: emotional, social, medical, legal Getting language right and how to gracefully recover from fumbles Sensitively approaching ongoing cancer care in transmasculine...
Evolving Role of BTK Inhibitors in CLL: Experts Answer Your Questions
November 09, 2022 21:30 - 10 minutes - 9.7 MBIn this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include: Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial today Relevance of overall response rate vs progression-free survival for BTK inhibitor therapy Approval of ibrutinib/venetoclax ...
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the SOHO 2022 Annual Meeting
October 28, 2022 20:30 - 21 minutes - 20.1 MBIn this episode, Christopher R. Flowers, MD, MS, and Kami Maddocks, MD, discuss their choices of recent important trials presented at the Society of Hematologic Oncology 2022 Annual Meeting evaluating the use of BTK inhibitors in chronic lymphocytic leukemia and mantle cell lymphoma. The discussion includes analyses of: GLOW: phase III randomized trial of ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for older or unfit patients with previously untreated chronic lymphocytic leu...
Relapsed/Refractory Myeloma: Navigating the Complex Treatment Landscape
October 24, 2022 20:30 - 1 hour - 72.3 MBIn this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a live webinar on therapeutic options currently available for patients with relapsed/refractory multiple myeloma. The topics covered include: How to sequence currently available therapies after relapse Challenges with using BCMA-targeted agents in clinical practice Experts’ thoughts on the potential approval of bispecific agents Presenters inclu...
Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting
October 24, 2022 20:30 - 15 minutes - 14.1 MBIn this episode,Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2022 Annual Global Meeting for ovarian and cervical cancers including: Post-hoc analyses from SOLO-3: olaparib vs physician’s choice chemotherapy in germline BRCA mutant platinum-sensitive recurrent ovarian cancer Phase III CALLA trial: durvalumab combined with and following chemoradiation for locally-advanced cervical cancer Phase III ARIEL3:...
Expert Insights on Key Updates From the 2022 ESMO Congress on PARP Inhibitors in Ovarian Cancer
October 04, 2022 20:30 - 19 minutes - 18.1 MBIn this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide their expert insights on key updates presented for ovarian cancer trials including: Phase III GOG-3004/SOLO-1: OS results after 7 years of follow-up for patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib vs placebo Phase III ENGOT-ov25/PAOLA-1: final OS results from the trial of maintenance therapy with olaparib with bevacizumab vs bevacizumab alone in women with newly diagno...
Managing EGFR-Mutated Non-Small-Cell Lung Cancer in Today’s Clinic: Expert Answers to Frequently Asked Questions
September 28, 2022 16:10 - 29 minutes - 27.3 MBIn this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (NSCLC) from a live meeting series. The episode includes expert insights on: • Identifying patients who may benefit the most from adjuvant osimertinib • Testing for EGFR mutations in early-stage NSCLC • Critical importance of getting molecular test results before starting immunotherapy • Monitoring cardiac toxicity in patients receiving os...
New Evidence With BTK Inhibitor Therapy in CLL and MCL From the Pan Pacific Lymphoma Conference 2022
August 30, 2022 17:40 - 28 minutes - 26.2 MBIn this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: BRUIN (CLL/small lymphocytic lymphoma [SLL]): phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor) SEQUOIA: phase III study evalu...
Experts Discuss Challenges in Advanced Hepatocellular Carcinoma Management
August 22, 2022 20:30 - 26 minutes - 24 MBIn this podcast episode from Clinical Care Options (CCO), Heinz-Josef Klumpen, MD, PhD, and Chris Verslype, MD, PhD, discuss challenges in selecting and sequencing therapy for patients with advanced hepatocellular carcinoma. Topics include: Factors to consider before selecting frontline immunotherapy Role of TKIs in the frontline Impact of Child-Pugh status on the efficacy of immunotherapy/VEGF inhibitor combination therapy Real-world evidence on frontline immunotherapy/VEGF combination ...
HER2-Positive Breast Cancer: Current Approaches for Quality Care
July 28, 2022 16:40 - 39 minutes - 36.2 MBIn this episode, Erika P. Hamilton, MD, and Komal Jhaveri, MD, discuss their approaches to and key studies for current management of patients with HER2-positive breast cancer. The discussion includes: Optimizing systemic therapy for patients with HER2-positive early breast cancer based on disease characteristics and risk Sequencing available therapies for patients with HER2-positive metastatic disease, including new data on first- and second-line therapy and how to manage patients with ce...
New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022
July 21, 2022 20:05 - 26 minutes - 24.3 MBIn this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLL FLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib ar...
New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022
July 06, 2022 20:00 - 32 minutes - 29.7 MBIn this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion will include analyses of: The SHINE trial evaluating the addition of ibrutinib to bendamustine/rituximab followed by rituximab maintenance in the first-line setting for older patients with MCL 3-year follow-up analysis from the CAPTIV...
Expert Insights on New Data From ASCO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
June 30, 2022 15:25 - 38 minutes - 35.3 MBIn this episode, Jubilee Brown, MD, and Elisabeth Diver, MD, provide expert insights on new data presented at ASCO 2022 for ovarian, endometrial, and cervical cancers regarding: Subgroup analyses from KEYNOTE-826 evaluating pembrolizumab in combination with chemotherapy with or without bevacizumab in persistent, recurrent, or metastatic cervical cancer Preliminary subgroup analyses from phase III ENGOT-EN5/GOG-3055 SIENDO trial of selinexor vs placebo maintenance in recurrent endometrial ca...
Expert Insight on Key Data From SGO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
May 19, 2022 20:00 - 46 minutes - 42.9 MBIn this episode, David Scott Miller, MD, FACOG, FACS, and Angeles Alvarez Secord, MD, MHSc, provide expert insights on key data presented at SGO 2022 for ovarian, endometrial, and cervical cancers regarding: Results from the prospective phase III PRIME study of an individualized dose for niraparib vs placebo maintenance in newly diagnosed advanced ovarian cancer Final OS analysis from phase III SOLO-3 evaluating olaparib vs physician’s choice of single-agent nonplatinum chemotherapy in gBR...
Call to Action and Reflection: Inclusive, Compassionate, and High-Quality Healthcare for Transgender Individuals
May 13, 2022 20:30 - 19 minutes - 18.2 MBIn this episode for all healthcare professionals and any patient-facing clinical staff, Nelson F. Sanchez, MD, shares key insights on the need for equitable, compassionate healthcare for transgender individuals, along with practical guidance based on his clinical experience caring for these patients. Topics include: Communication and physical exam skills Specific clinical care needs of transgender individuals related to transition Creating an inclusive and welcoming environment for transg...
Inclusive Healthcare for Transgender Individuals: Insights From a Healthcare Professional’s Transition Experience
May 02, 2022 20:30 - 16 minutes - 15.4 MBIn this episode, Pharmacist Olivia Buckoski shares her experience undergoing medical and social transition and offers advice from the perspective of both a transgender person and healthcare professional on caring for transgender individuals. Topics include: Importance of educating entire care team about needs of transgender individuals, starting with the waiting room Specific advice for the exam room Pharmacy and adherence considerations with hormone therapy Examples of uninformed care
Anti-TIGIT Therapy: Overview of Current Clinical Evidence and Key Ongoing Trials
April 15, 2022 19:10 - 22 minutes - 20.3 MBIn this episode, Jyoti D. Patel, MD, and Ani Balmanoukian, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising results in PD-L1-positive NSCLC. The episode includes a review of phase II data on the use of tiragolumab plus atezolizumab in NSCLC, the use of PD-L1 as a marker of response, the potential role of anti-TIGIT therapies in solid tumors, and ongoing trials in lung cancer including SKYSCRAPER-01, SKYSCRAPER-02, SKYSCRAPE...
Targeting TIGIT: Understanding New Approaches for Inhibiting the Immune Checkpoint Pathway
April 07, 2022 18:35 - 20 minutes - 19 MBIn this episode, Jyoti D. Patel, MD, and Diwakar Davar, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising early-phase clinical trial results. The episode includes a comprehensive explanation of TIGIT, how the TIGIT pathway functions, and the potential role of TIGIT inhibition for the treatment of cancer, including analyses from ongoing clinical trials such as CITYSCAPE, PACIFIC-8, ARC-7, and SKYSCRAPER-01. Presenters: Jyot...
Evolving Treatment Landscape With Regorafenib and TAS-102 in Metastatic Colorectal Cancer
April 06, 2022 17:00 - 21 minutes - 19.7 MBIn this episode, Nilofer S. Azad, MD, and Kanwal Raghav, MD, discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC, with topics including: Current use of regorafenib and TAS-102 monotherapy Combination therapy with regorafenib and PD-1 inhibitors Adding bevacizumab to TAS-102 Presenters: Nilofer S. Azad, MD Professor, Oncology Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore, Maryland Kanwal Raghav...
Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL
March 31, 2022 21:15 - 28 minutes - 25.8 MBIn this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including: For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered? What is the optimal therapy for a patient with del(17p) CLL? Wh...